Sierra Oncology, Inc. (SRRA)

17.24 -0.82 (-4.54%) At close: 4:00PM EDT

Sierra Oncology, Inc.

1820 Gateway Drive
Suite 110
San Mateo, CA 94404
United States
650 376 8679
http://www.sierraoncology.com

Sector(s): Healthcare
Industry: Biotechnology
Full Time Employees: 69

Key Executives

Name	Title	Pay	Exercised	Year Born
Dr. Barbara Klencke	Chief Devel. Officer	673.69k	N/A	1957
Dr. Mark M. Kowalski	Chief Medical Officer	599.79k	N/A	1955
Dr. Stephen G. Dilly MBBS, Ph.D.	Pres, CEO & Director	N/A	N/A	1960
Mr. Sukhi Jagpal CA, CPA, CBV, MBA	Chief Financial Officer	N/A	N/A	1974
Ms. Christina Thomson M.S., J.D.	Gen. Counsel & Corp. Sec.	N/A	N/A	N/A
Mr. William D. Turner	Chief Regulatory & Technical Operations Officer	N/A	N/A	N/A
Mr. Kevin Norrett M.B.A., M.S.	Chief Bus. Officer	N/A	N/A	N/A

Amounts are as of December 31, 2019 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Sierra Oncology, Inc. researches, develops, and commercializes therapies for the treatment of patients with hematology and oncology needs. Its lead drug candidate, momelotinib, is a selective and orally-bioavailable JAK1, JAK2, and ACVR1 inhibitor that has two completed Phase 3 trials for the treatment of myelofibrosis. The company also develops SRA737, an orally bioavailable small molecule inhibitor of Checkpoint kinase 1; and SRA141, an orally bioavailable small molecule inhibitor of cell division cycle 7 kinase. The company was formerly known as ProNAi Therapeutics, Inc. and changed its name to Sierra Oncology, Inc. in January 2017. Sierra Oncology, Inc. was incorporated in 2003 and is based in San Mateo, California.

Corporate Governance

Sierra Oncology, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.